Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?
about
Antineoplastic-related cardiotoxicity, morphofunctional aspects in a murine model: contribution of the new tool 2D-speckle tracking.Cardiovascular disease in cancer survivors.Long-Term and Latent Side Effects of Specific Cancer Types.Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib.Efficacy and safety of trastuzumab as maintenance or palliative therapy in advanced HER2-positive gastric cancerTrastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers
P2860
Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 February 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Trastuzumab and target-therapy ...... from Type II cardiomyopathies?
@en
Trastuzumab and target-therapy ...... from Type II cardiomyopathies?
@nl
type
label
Trastuzumab and target-therapy ...... from Type II cardiomyopathies?
@en
Trastuzumab and target-therapy ...... from Type II cardiomyopathies?
@nl
prefLabel
Trastuzumab and target-therapy ...... from Type II cardiomyopathies?
@en
Trastuzumab and target-therapy ...... from Type II cardiomyopathies?
@nl
P2093
P2860
P50
P1476
Trastuzumab and target-therapy ...... from Type II cardiomyopathies?
@en
P2093
Carlo Maurea
Emanuela Esposito
Giovanna Piscopo
Immacolata Capasso
Nicola Maurea
P2860
P304
P356
10.1080/21645515.2015.1125056
P577
2016-02-02T00:00:00Z